{"id":37092,"date":"2025-01-20T10:07:43","date_gmt":"2025-01-20T09:07:43","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=37092"},"modified":"2025-01-15T14:11:01","modified_gmt":"2025-01-15T13:11:01","slug":"registerdaten-unterstuetzen-den-einsatz-von-prasugrel-nach-therapie-des-akuten-myokardinfarkts-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2025\/registerdaten-unterstuetzen-den-einsatz-von-prasugrel-nach-therapie-des-akuten-myokardinfarkts-cme","title":{"rendered":"Registerdaten unterst\u00fctzen den Einsatz von Prasugrel nach Therapie des akuten Myokardinfarkts [CME]"},"content":{"rendered":"<p>Nach einem mittels perkutaner Koronarintervention (PCI) behandelten Akuten Koronarsyndrom (ACS) ist eine duale Antipl\u00e4ttchentherapie (DAPT) mit einem der beiden P2Y12-Inhibitoren Prasugrel oder Ticagrelor f\u00fcr 12\u00a0Monate zus\u00e4tzlich zu Acetylsalicyls\u00e4ure (ASS) leitliniengem\u00e4\u00dfer Therapiestandard. Ein direkter Kopf-an-Kopf-Vergleich zwischen Prasugrel und Ticagrelor stand lange Zeit aus, bis 2019 die ISAR-REACT-5-Studie publiziert wurde, die einen signifikanten Vorteil f\u00fcr Prasugrel zeigte: [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nach einem mittels perkutaner Koronarintervention (PCI) behandelten Akuten Koronarsyndrom (ACS) ist eine duale Antipl\u00e4ttchentherapie (DAPT) mit einem der beiden P2Y12-Inhibitoren Prasugrel oder Ticagrelor f\u00fcr 12\u00a0Monate zus\u00e4tzlich zu Acetylsalicyls\u00e4ure (ASS) leitliniengem\u00e4\u00dfer Therapiestandard. Ein direkter Kopf-an-Kopf-Vergleich zwischen Prasugrel und Ticagrelor stand lange Zeit aus, bis 2019 die ISAR-REACT-5-Studie publiziert wurde, die einen signifikanten Vorteil f\u00fcr Prasugrel zeigte: [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,71,5325,498,65,83,84,87,1033,79,727,2005],"class_list":["post-37092","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-herzinfarkt","tag-isar-react-5-studie","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-thrombozytenaggregationshemmer","tag-ticagrelor"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/37092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=37092"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/37092\/revisions"}],"predecessor-version":[{"id":37093,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/37092\/revisions\/37093"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=37092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=37092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=37092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}